Plant Name: Vitex trifolia
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| GPBAR1; ADORA3; FFAR1; FFAR4; | |
| PTPN1; PTPN2; PTPRF; ACP1; | |
| GLA; FAAH; RECQL; TDP1; TERT; GLO1; HPGD; HSD11B1; ALOX12; AKR1B1; HSD17B10; AKR1B10; NOX4; ALOX15; USP2; TNKS; PARP1; TNKS2; POLB; CD38; | |
| FLT3; MAPK1; GSK3B; | |
| CA2; CA1; CA12; CA9; CA3; CA5B; CA7; CA5A; CA4; CA6; | |
| PPARA; PPARD; PPARG; | |
| RORC; | |
| NR1H4; | |
| ALOX5; MAOA; XDH; | |
| KDM4E; | |
| MMP12; MMP2; MMP9; | |
| TLR2; | |
| HIF1A; TP53; | |
| ABCG2; | |
| HTT; LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; APP; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.583E-07 | 4.155E-05 | ALOX12, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.301E-07 | 7.899E-05 | ALOX12, ALOX15, ALOX5, HPGD |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.286E-07 | 1.511E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.070E-06 | 2.118E-04 | CYP1A1, POLB, PPARG, TP53 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.124E-06 | 2.185E-04 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.304E-06 | 2.469E-04 | HPGD, MMP2, MMP9, TERT |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.574E-06 | 2.857E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.169E-06 | 3.719E-04 | CA2, CA7, HIF1A, HTT, MAPK1, NR1H4, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.236E-06 | 3.804E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.865E-06 | 4.622E-04 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 4.804E-06 | 7.117E-04 | FFAR4, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 5.354E-06 | 7.720E-04 | APP, GSK3B, HIF1A, MAPK1, MAPT, PARP1, PTPN1, PTPN2, PTPRF, TERT, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 5.467E-06 | 7.731E-04 | ALOX12, ALOX15, ALOX5, TLR2 |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 5.811E-06 | 8.059E-04 | CD38, FFAR1, HIF1A, NR1H4, PPARD |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 5.888E-06 | 8.115E-04 | ADORA3, APP, CYP1B1, FABP4, GLA, GSK3B, MAPT, MMP9, NR1H4, PPARA, PPARG, PTPN1, PTPN2, PTPRF, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.097E-06 | 8.350E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 6.791E-06 | 9.128E-04 | ABCG2, APP, CD38, FLT3, GLA, HPGD, HTT, MAPK1, MAPT, MMP9, PARP1, PPARG, SMN1, SMN2, TERT, TP53, TTR, USP2, XDH |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 8.361E-06 | 1.084E-03 | GSK3B, HTT, MAPT |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.142E-05 | 1.438E-03 | CA2, CA7, CD38, HIF1A, HTT, MAPK1, NR1H4, PARP1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.294E-05 | 1.592E-03 | FABP3, FFAR1, NR1H4, PPARG, TLR2 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.409E-05 | 1.658E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.409E-05 | 1.658E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.662E-05 | 1.925E-03 | CYP1B1, GSK3B, HPGD, HTT, MAPT, MMP9, NOX4, PPARG, PTPN2, TP53, XDH |
| BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 2.281E-05 | 2.547E-03 | TERT, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 2.297E-05 | 2.552E-03 | AKR1B10, CYP1A1, CYP1B1, PPARD, TTR |
| BP | GO:0009987; cellular process | GO:2001242; regulation of intrinsic apoptotic signaling pathway | 2.950E-05 | 3.164E-03 | HIF1A, MMP9, PARP1, PTPN1, PTPN2, TP53 |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 3.056E-05 | 3.224E-03 | FFAR1, HIF1A, NOX4, NR1H4, PPARG, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 3.390E-05 | 3.449E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 3.390E-05 | 3.449E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 3.467E-05 | 3.512E-03 | PPARA, PPARG, RORC, TP53, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 4.216E-05 | 4.009E-03 | APP, TLR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.216E-05 | 4.009E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 4.216E-05 | 4.009E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.216E-05 | 4.009E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.216E-05 | 4.009E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.216E-05 | 4.009E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 4.216E-05 | 4.009E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 4.613E-05 | 4.368E-03 | HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 5.146E-05 | 4.830E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 5.277E-05 | 4.911E-03 | APP, CYP1A1, CYP1B1, FLT3, MAPK1, NOX4, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 5.527E-05 | 5.084E-03 | AKR1B1, CYP1A1, CYP1B1, CYP3A4, TTR |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 5.527E-05 | 5.084E-03 | AKR1B1, CYP1B1, MAPK1, MMP9, TP53 |
| BP | GO:0050896; response to stimulus | GO:1901654; response to ketone | 5.745E-05 | 5.256E-03 | AKR1B1, CA9, CD38, PARP1, PPARG, TLR2 |
| BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 5.800E-05 | 5.263E-03 | ALOX12, APP, CD38, FFAR4, GSK3B, HIF1A, LMNA, NR1H4, PPARD, PPARG, PTPN2, TERT, TLR2, XDH |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.559E-05 | 5.829E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 7.574E-05 | 6.571E-03 | HIF1A, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 8.211E-05 | 6.991E-03 | AKR1B1, AKR1B10, APP, CYP1B1, CYP3A4, PPARD, TTR |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 8.411E-05 | 6.991E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 8.411E-05 | 6.991E-03 | PTPN1, PTPN2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 8.411E-05 | 6.991E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.411E-05 | 6.991E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.411E-05 | 6.991E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.686E-05 | 7.165E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 8.769E-05 | 7.191E-03 | AKR1B1, AKR1B10, HPGD, HSD11B1, HSD17B10 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 9.900E-05 | 7.897E-03 | CYP1A1, CYP1A2, PPARG |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 1.084E-04 | 8.426E-03 | ABCG2, AKR1B1, AKR1B10, APP, CA4, CA5A, CA5B, CD38, CYP1A1, CYP1A2, CYP1B1, CYP3A4, FABP4, FLT3, GLA, GLO1, GSK3B, HIF1A, HSD17B10, HTT, KDM4E, LMNA, MAOA, MAPK1, MAPT, MMP12, MMP2, NOX4, PARP1, POLB, PPARA, PPARD, PPARG, PTPN1, PTPN2, RECQL, RORC, SMN1, SMN2, TDP1, TERT, TLR2, TNKS, TNKS2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.122E-04 | 8.572E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.202E-04 | 9.119E-03 | FABP3, PPARA, PPARD, PPARG |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.202E-04 | 9.119E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.237E-04 | 9.322E-03 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 1.267E-04 | 9.388E-03 | CA2, CYP1A1, CYP1A2, FLT3, HIF1A, HPGD, HSD11B1, HTT, MAPK1, POLB, PPARA, PPARD, PPARG, USP2 |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 1.265E-04 | 9.388E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.331E-04 | 9.724E-03 | NR1H4, PPARA, PPARD, PPARG, RORC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.248E-22 | 2.014E-17 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.354E-17 | 4.003E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.010E-16 | 3.053E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.292E-14 | 3.517E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, GLO1, MMP12, MMP2, MMP9, NR1H4, PARP1, PPARA, PPARD, PPARG, PTPN1, RORC, TNKS, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.206E-21 | 7.277E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 5.791E-09 | 5.010E-07 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.381E-06 | 1.462E-04 | APP; MAOA; ALOX5; ALOX15; MAPK1; ALOX12 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.222E-06 | 1.281E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.382E-05 | 2.870E-04 | GSK3B; FLT3; MMP2; MAPK1; PPARG; HIF1A; TP53; MMP9; PPARD |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.981E-06 | 2.415E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.351E-05 | 2.870E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.236E-05 | 2.870E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.493E-05 | 2.870E-04 | MMP2; MAPK1; MMP9; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 9.821E-05 | 1.655E-03 | MMP2; MAPK1; TP53; HIF1A; MMP9; TLR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.052E-04 | 1.655E-03 | FLT3; MAPK1; TP53; HIF1A |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.549E-04 | 1.722E-03 | PTPN1; MAPK1; ACP1; PTPRF |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.319E-04 | 1.722E-03 | CA2; NR1H4; CYP3A4; ABCG2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.932E-04 | 4.425E-03 | MAOA; ALOX15; AKR1B1; ALOX12; CYP3A4; HSD17B10; HSD11B1; AKR1B10; ALOX5; CYP1A2; CYP1A1; CD38; XDH |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.732E-04 | 3.587E-03 | APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.115E-04 | 4.425E-03 | HPGD; FLT3; PPARG; TP53; MMP9 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.805E-04 | 5.606E-03 | PTPN1; GSK3B; PPARA; PTPRF |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 9.157E-04 | 6.601E-03 | GSK3B; MAPK1; TP53; HIF1A |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.592E-04 | 1.722E-03 | MAPK1; PPARG; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.427E-03 | 9.019E-03 | GSK3B; MAPK1; PPARA; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.722E-03 | 9.367E-03 | PARP1; LMNA; MAPK1; TP53 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.085E-04 | 6.357E-03 | ALOX5; CYP1A1; CYP1B1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.068E-04 | 6.601E-03 | GSK3B; MAPK1; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.592E-04 | 1.722E-03 | CYP1A2; ALOX15; CYP3A4 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.185E-03 | 8.201E-03 | FLT3; MAPK1; PPARD |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.008E-03 | 1.046E-02 | MAPK1; TP53; MMP9; TLR2 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.678E-03 | 9.367E-03 | PTPN1; GSK3B; MAPK1; PTPRF |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.765E-04 | 1.796E-03 | AKR1B10; AKR1B1; GLA |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.310E-03 | 8.715E-03 | AKR1B10; AKR1B1; GLA |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.512E-03 | 9.019E-03 | GSK3B; MAPK1; TP53 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.512E-03 | 9.019E-03 | ALOX5; ALOX15; ALOX12 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.232E-03 | 2.034E-02 | GSK3B; MAPK1; TP53 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 5.695E-03 | 2.663E-02 | MMP2; MAPK1; MMP9 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.733E-03 | 9.367E-03 | CYP1A2; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.057E-03 | 1.046E-02 | MAOA; CYP1A2; CYP3A4 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 9.226E-03 | 3.885E-02 | ALOX5; MAPK1; TLR2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 9.657E-03 | 3.885E-02 | GSK3B; MAPK1; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.657E-03 | 3.885E-02 | ADORA3; MAPK1; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.226E-02 | 4.821E-02 | CYP3A4; XDH |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 7.640E-03 | 3.304E-02 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 6.072E-03 | 2.764E-02 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 6.449E-03 | 2.861E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.164E-03 | 1.564E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.305E-04 | 1.722E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9; MAPK1; MMP9; TLR2; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; CD38 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH; MAOA |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1; FFAR1; AKR1B1; GSK3B; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; MMP12 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT; APP; PPARG; PPARG |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; PARP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; PPARD; PPARD; PPARG |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; CA1; CA1; AKR1B1 |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; MAOA; MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR; APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2; TERT; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MMP12; FAAH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; TLR2; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; FFAR1; PPARD; PPARG; PPARG |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; FFAR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; HSD11B1; PPARD; MMP12 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9; TERT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; AKR1B1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; HIF1A; TP53; CA1; FLT3; FLT3; CA9; MAPK1; MMP9; TLR2; PARP1; MMP2; GSK3B; CD38; APP |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; PARP1; MMP2 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; CD38 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |